Floatz logo

Snb-101

Patient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC)

SN BioScienceSmall moleculePhase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

290 Active assets in the Patient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC) cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
vx-970
National Cancer Institute (NCI)
Phase 2BBB
Adebelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
Veliparib
Central European Society for Anticancer Drug Research
Phase 2BB
Carboplatin
University of Maryland, Baltimore
Phase 4BB

View all 50 →

Same molecule, other indications

Snb-101 is also rated in:

malignant pancreatic neoplasmDormant
CC
Indicative ·
42 / 100
View asset →
head and neck cancerDormant
CC
Indicative ·
42 / 100
View asset →
gastric cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →